Mapping the Impact of Treatments on Symptoms, Functioning, and Transition in Youth At-Risk of Psychosis: A Scoping Review
Poster B83, Tuesday, October%209, 11:30%20am%20-%201:00%20pm, Essex%20Ballroom
Megan Farris1, Dan Devoe1, Jean Addington1; 1Hotchkiss Brain Institute, Department of Psychiatry, University of Calgary, Alberta Canada
Treatments in youth at clinical high risk (CHR) for psychosis have varied, yet a review of all treatments and their impact on various outcomes has not been descriptively mapped. Thus, the aim of this study was to survey the treatment literature in CHR samples, document treatment types, chart the impact of these treatments on various outcomes, and identify gaps in our understanding. We searched Medline, PsychINFO, CINAHL, Embase and EBM databases with no date, language, or geographical restrictions. Studies were included if they implemented any intervention in a CHR sample and collected follow-up data measuring transition or symptomatic outcomes. Identified studies were then descriptively synthesized to determine the current state of the literature. Of 5,801 citations identified, a total of 76 studies met the inclusion criteria. A total of 4,502 CHR participants received treatment with a mean age of 19.4 years (SD=4.6) and 2,344 (52.9%) were male. Eighteen unique interventions and 14 different outcomes were reported at follow-up. The most common outcome measures were attenuated psychotic symptoms (n=41) and transition (n=39), followed by global functioning (n=35), negative symptoms (n=32), total symptoms (n=29), general symptoms (n=28), social functioning (n=24), disorganized symptoms (n=24), depression (n=21), cognition (n=20), anxiety (n=15), role functioning (n=11), quality of life (n=9), and mania (n=5). This review identified an important body of treatment literature that describes all researched treatments and outcomes in CHR samples. Additional research is needed to determine an ideal treatment strategy for alleviating the plethora of symptoms that CHR individuals face.
Topic Area: Ultra High Risk / Prodromal Research